Contact this trialFirst, we need to learn more about you.
Exon Skipping Agent
PGN-EDO51 for Duchenne Muscular Dystrophy
Recruiting1 awardPhase 2
Toronto, Ontario
This trial is being conducted to assess the safety and tolerability of giving multiple increasing doses of PGN-EDO51 through an IV to individuals with Duchenne muscular dystrophy. The trial will have
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.